Clinical Trial Methodology & Reviews

Brooker H, Meinel N (2008). Brain Power: Translational medicine. European Pharmaceutical Contractor. 32-36


Byrom B, Mundt J (2005). The value of computer-administered self-report data in central nervous system clinical trials. Current Opinion in Drug Discovery and Development 89: 374-383.


Cusack M (2008). Cerebral Intelligence. European Pharmaceutical Contractor. Spring, 48-51.


Ellis KA, Mehta MA, Wesnes KA, Armstrong S, Nathan PJ (2005). Combined D1/D2 receptor stimulation under conditions of dopamine depletion impairs spatial working memory performance in humans. Journal of Psychopharmacology. 181: 771–780.


Hall ST, Puech A, Schaffler K, Wesnes KA, Gamzu ER (1990). Early clinical testing of cognition enhancers: prediction of efficacy. Journal of Pharmacopsychiatry. 23: 57-58.


Harrison JE, Wesnes KA (2006). Objective cognitive testing and patient-reported accounts of cognitive function. Patient Reported Outcomes. 36: 5-8.


Horton RJ, Minniti A, Mireylees S, McEntegart D (2008). A randomized trial to determine the impact on compliance of a psychophysical peripheral cue based on the Elaboration Likelihood Model. Contemporary Clinical Trials. 29: 823-828


Meinel N, Satek S, Edgar C, Wesnes KA (2007). Translational Medicine. ICT Clinical Trial Management. 12-18


Mundt JC, Geralts DS, Moore HK (2006). Dial "T" for testing: Technological flexibility in neuropsychological assessment. Telemedicine journal and e-health: the official journal of the American Telemedicine Association. 12(3): 317-323


Papp KV, Walsh SJ, Snyder PJ (2009) Immediate and delayed effects of cognitive interventions in healthy elderly: A review of current literature and future directions. Alzheimer’s and Dementia. 5: 56-60


Prasad C, Packer L, Benzie IFF, Hamazaki T, Riedel WJ, Wesnes KA (2003) Nutraceutical Research & Education Now: We can’t afford to wait. Current Topics in Nutraceutical Research 1: vii.


Wesnes KA (2000). The value of assessing cognitive function in drug development. Dialogues in Clinical Neuroscience. 2. 183-202.


Wesnes KA (2001). Latest developments in cognitive function assessment in drug development. GOR 3: 140-144.


Wesnes KA (2001). The assessment of cognitive function in clinical trials. Good Clinical Practice Journal. 8: 10-14.


Wesnes KA (2001). The use of cognitive tests to facilitate drug and dose selection Phase I and to optimise dosing in Phase IV. International Congress Series 1220. 35-50.


Wesnes KA (2002). Assessing cognitive function in clinical trials: latest developments and future directions. Drug Discovery Today. 7(1): 29-35.


Wesnes KA (2005). An automated system for assessing cognitive function in any environment. Proceedings of SPIE. 5797: 24-41.


Wesnes KA (2006). Cognitive function testing: the case for standardisation and automation. Journal of the British Menopause Society. 12: 158-163.


Wesnes KA (2010). An evaluation of techniques to identify beneficial effects of nutrition and natural products on cognitive function. Nutrition Reviews 68 (Suppl. 1): S22–S28.


Wesnes KA (2010). The opportunities for treating the cognitive declines which accompany normal ageing. Journal for Clinical Studies May 2010: 36-42.


Wesnes KA (2010). Wake-Up to the MATRICS: Cognition Enhancement – Expanding Opportunities in Drug Development. International Clinical Trials June 2010: 66-72.


Wesnes KA (2013) Natural substances as treatments for age-related cognitive declines. In: Advances in Natural Medicines, Nutraceuticals and Neurocognition. In C. Stough & A. Scholey (Eds), CRC Press, Taylor & Francis, Boca Raton. ISBN 9781439893609.


Wesnes KA, Brooker H (2010). Pharmacodynamic Evaluation: CNS. In HG Vogel, J Maas, A Gebauer  (eds.) Drug Discovery and Evaluation: Methods in Clinical Pharmacology, Springer Verlag Berlin, ISBN: 978-3-540-89890-0.


Wesnes KA, Edgar C (2002). Latest developments in the assessment of human cognitive function in clinical trials. European Pharmaceutical Contractor. 74-83.


Wesnes KA, Pincock C (2002). Practice effects on cognitive tasks: a major problem? Lancet Neurology. 1: 8 - 473.


Wesnes KA, Simpson PM, Christmas L (1987). The assessment of human information processing abilities in psychopharmacology. Human Psychopharmacology: Measures and Methods. 79-92.


Wesnes, K. A. (2003). The Cognitive Drug Research computerised assessment system: Application to clinical trials. Memory: Basic Concepts, Disorders and Treatment. P. De Deyn, E. Thiery and R. D’Hooge. Uitgeverij Acco, Leuven: 453–472.


Woodruff-Pak DS, Jaeger ME, Gorman C, Wesnes KA (1999). Relationships among age, conditioned stimulus-unconditioned stimulus interval, and neuropsychological test performance. Neuropsychology. 13: 90-102.


Zangara A, Wesnes KA (2013). Herbal cognitive enhancers: New developments and challenges for therapeutic applications. In: M.K.Thakur & I.S. Suresh (Eds). Brain Aging and Therapeutic Interventions, Springer. ISBN 978-94-007-5237-5. pp 267-289.


de Jager CA, Dye L, de Bruin EA, Butler L, Fletcher J, Lamport D, Latulippe ME, Spencer JPE, Wesnes KA. (2014). Markers of cognitive function: Criteria for validation and considerations for investigating the effects of foods andnutrients. Nutrition Reviews 72: 162-179.


Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS (2015). Practice Effects Due to Serial Cognitive Assessment: Implications for Preclinical Alzheimer’s Disease Randomized Controlled Trials. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1: 103–111.


Get in touch...




  • Twitter B&W